PROCEPT BioRobotics Corporation
NASDAQ:PRCTMedical - Devices
+$0.19 today
- Market cap
- $1.45B
- Beta
- 0.85
- P/E (TTM)
- -11.6
- EPS (TTM)
- -$1.81
Volume 2.05M
Average 1.46M
PRCT Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
PROCEPT BioRobotics CorporationNASDAQ: PRCT
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses grows, but more slowly than its trailing trend
Q1 FY2026 operating expenses of $86.55M rose 20.9% year over year, behind the +23.4% change in trailing-twelve-month operating expenses. Sequentially, it rose 11.9% from the prior quarter. Over 3 fiscal years it compounded at +36.6% a year.
Context
- Operating expenses amounted to 97.4% of revenue in FY2025, down 6.7 pp from a year earlier.
- Operating expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +20.9% toward the trailing-twelve-month pace of +23.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 300.09M USD
- Year-over-year change
- +28.4%
- 4-year CAGR
- +43.9%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 300.09M | +28.4% |
| FY2024 | 2024-12-31 | 233.71M | +29.7% |
| FY2023 | 2023-12-31 | 180.22M | +53.0% |
| FY2022 | 2022-12-31 | 117.81M | +68.2% |
| FY2021 | 2021-12-31 | 70.03M | — |
Operating Expenses vs competitors
How PRCT compares with its peers on the latest reported figures
- PRCT's LTM Mar 2026 operating expenses of $311.83M is the highest of the 5 companies compared; the peer median is $40.58M.
- Its year-over-year change of +23.4% is the 3rd highest of 4, against a peer median of +24.6%.
- Operating expenses amounts to 96.8% of revenue for PRCT, versus a peer median of 102.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $311.83M | +23.4% | +36.6% | 96.8% | |
FOCLEDAP TMS S.A. American Depositary Shares | LTM Mar 2026 | $57.9M | — | +21.6% | 78.1% |
| LTM Mar 2026 | $51.59M | +24.6% | +16.2% | 127.0% | |
| LTM Mar 2026 | $29.57M | +10.8% | +65.1% | 61.0% | |
| LTM Mar 2026 | $16.03M | +31.0% | +3.5% | 15268.6% | |
| Peer median (excluding PRCT) | $40.58M | +24.6% | +18.9% | 102.6% | |
Competitors are the stored peer set for PRCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 34.47M | 75.01M | 136.19M | 224.5M | 308.05M |
| Cost of Revenue | 18.61M | 37.93M | 65.14M | 87.4M | 111.83M |
| Gross Profit | 15.87M | 37.09M | 71.05M | 137.1M | 196.23M |
| Gross Margin | 46.0% | 49.4% | 52.2% | 61.1% | 63.7% |
| Research & Development | 18.99M | 28.98M | 48.45M | 62.3M | 71.28M |
| Selling, General & Admin | 51.04M | 88.83M | 131.77M | 171.42M | 228.81M |
| Operating Expenses | 70.03M | 117.81M | 180.22M | 233.71M | 300.09M |
| Depreciation & Amortization | 3.32M | 2.84M | 3.81M | 5.23M | 6.39M |
| EBITDA | (50.72M) | (79.13M) | (98.1M) | (82M) | (85.41M) |
| EBITDA Margin | -147.1% | -105.5% | -72.0% | -36.5% | -27.7% |
| Operating Income | (54.16M) | (80.72M) | (109.17M) | (96.61M) | (103.86M) |
| Operating Margin | -157.1% | -107.6% | -80.2% | -43.0% | -33.7% |
| Interest Income | 76K | 2.5M | 7.55M | 10.9M | 12.22M |
| Interest Expense | 5.81M | 5.18M | 4M | 4.18M | 3.59M |
| Other Income / Expenses | (5.69M) | (6.43M) | 3.27M | 5.2M | 8.48M |
| Income Before Tax | (59.85M) | (87.15M) | (105.9M) | (91.41M) | (95.38M) |
| Pre-Tax Margin | -173.6% | -116.2% | -77.8% | -40.7% | -31.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 190K |
| Net Income | (59.85M) | (87.15M) | (105.9M) | (91.41M) | (95.57M) |
| Net Margin | -173.6% | -116.2% | -77.8% | -40.7% | -31.0% |
| EPS (Basic) | (1.37) | (1.96) | (2.24) | (1.75) | (1.72) |
| EPS (Diluted) | (1.37) | (1.96) | (2.24) | (1.75) | (1.72) |
| Weighted Avg Shares | 43.7M | 44.4M | 47.26M | 52.13M | 55.54M |
| Weighted Avg Shares (Diluted) | 43.7M | 44.4M | 47.26M | 52.13M | 55.54M |
PROCEPT BioRobotics Corporation
NASDAQ:PRCT
Intrinsic Alpha fair value
Locked
Current Price
$25.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.